Case Report

Acute Respiratory Distress Syndrome in a Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19)

Christine A. Blauvelt, MD,
Catherine Chiu, MD,
Anne L. Donovan, MD,
Mary Prahl, MD,
Thomas K. Shimotake, MD,
Ronald B. George, MD, FRCPC,
Brian S. Schwartz, MD,
Naghma A. Farooqi, MD,
Syed S. Ali, MD,
Arianna Cassidy, MD,
Juan M. Gonzalez, MD, PhD,
and Stephanie L. Gaw, MD, PhD

BACKGROUND: Data suggest that pregnant women are not at elevated risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or developing severe disease compared with nonpregnant patients. However, management of pregnant patients who are critically ill with coronavirus disease 2019 (COVID-19) infection is complicated by physiologic changes and other pregnancy considerations and requires balancing maternal and fetal well-being.

CASE: We report the case of a patient at 28 weeks of gestation with acute respiratory distress syndrome (ARDS) from COVID-19 infection, whose deteriorating respiratory condition prompted delivery. Our patient's oxygenation and respiratory mechanics improved within hours of delivery, though she required prolonged mechanical ventilation until postpartum day 10. Neonatal swabs for SARS-CoV-2 and COVID-19 immunoglobulin (Ig) G and IgM were negative.

CONCLUSION: We describe our multidisciplinary management of a preterm pregnant patient with ARDS from COVID-19 infection and her neonate. (Obstet Gynecol 2020;136:46–51)

DOI: 10.1097/AOG.0000000000003949

Teaching Points

1. Management of critically ill pregnant patients with coronavirus disease 2019 (COVID-19) infection requires balancing maternal and fetal well-being, as well as minimizing undue risk to health care professionals.

2. In pregnant patients with moderate-to-severe acute respiratory distress syndrome requiring positive-pressure ventilation, early delivery can decrease maternal oxygen requirements and improve respiratory mechanics, which may improve maternal outcomes under the appropriate clinical circumstances.

3. Preterm neonates may be at particular risk for perinatal COVID-19 infection owing to the fetal environment and immature passive immunity and skin integrity, and additional testing and isolation measures may be warranted in the exposed premature neonate requiring ongoing hospitalization.

CASE

At 28 4/7 weeks of gestation, a 34-year-old woman, G6P3113, presented to her local hospital with a 4-day history of malaise, fever, myalgias, cough, and shortness of breath. Her medical history was significant for moderate asthma, A2 gestational diabetes mellitus, class II obesity, and three prior cesarean deliveries. She reported no uterine contractions, leakage of fluid, vaginal bleeding, or decreased fetal movement. She worked as a medical assistant but had no known exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reported no tobacco use.

On arrival, her vital signs were as follows: temperature 37.4°C, blood pressure 142/69 mm Hg, heart rate 103 beats per minute, respiratory rate 30–40/min, and SpO2 93% on non-rebreather mask at 15 L/min. She was transferred to a tertiary care referral center with a labor and delivery unit and a level IV neonatal intensive care unit. Vital signs were as follows: temperature 36.9°C, blood pressure 117/66 mm Hg, heart rate 110 beats per minute, respiratory rate 30–40/min, and SpO2 93% on non-rebreather mask at 15 L/min. She was transitioned to high-flow nasal cannula, which can provide up to 50 L/min of oxygen, and was uptitrated to 30 L/min with FiO2 100% with no improvement in her saturation or work of breathing. Given concern for impending respiratory decompensation, the patient was intubated. Her hemodynamics and oxygen levels remained stable during intubation. Initial PaO2/FiO2 ratio was 163 (normal greater than 300), plateau pressure was 15 cmH2O, static compliance was 80 mL/cmH2O (normal greater than 100), and calculated dead space fraction was 42% (normal approximately 25–30%) (Fig. 1A).

The patient was started on compassionate use remdesivir 22 hours after admission. Hydroxychloroquine was discontinued owing to new prolonged QTc (506 ms) and access to remdesivir. Antibiotics were discontinued owing to low concern for bacterial pneumonia. Over the subsequent 12 hours, the patient required deep sedation to tolerate lung-protective ventilation. Despite implementing low tidal volume 400 mL (based on predicted body weight 57 kg) and incremental titration of positive end-expiratory pressure (PEEP) from 10 to 16 cmH2O, her FiO2 requirement remained high at 80% and her static compliance (a measure of lung stiffness) worsened (Fig. 1A). No further oxygenation benefit was seen with neuromuscular blockade. Fetal status was reassuring throughout, and an ultrasound scan revealed an appropriate-for-gestational-age sized fetus with an estimated weight of 1,920 g. A multidisciplinary group agreed to proceed with cesarean delivery for maternal benefit.

The patient received her second dose of betamethasone and was started on magnesium sulfate for fetal neuroprotection and a continuous insulin infusion for A2 gestational diabetes mellitus. Before transfer to the operating room, her ventilator was transitioned to a portable model, FiO2 was increased to 100%, and inhaled nitric oxide was initiated at 20 ppm to temporarily improve oxygenation peripherally. Her PaO2 improved to 159 mm Hg (from 94 mm Hg).

Following a safety protocol to minimize exposure (Appendix 1, available online at http://links.lww.com/AOG/B896), the patient was transported to the designated COVID-19 obstetric operating room and underwent an uncomplicated repeat cesarean delivery at 28 6/7 weeks of gestation of an 1,880-g liveborn male neonate. Delayed cord clamping was not performed to reduce neonatal exposure to maternal anesthesia and SARS-CoV-2. The 1- and 5-minute Apgar scores were 4 and 8, respectively. Amniotic fluid was clear. The patient received oxytocin and mether- gine for uterine atony, with estimated blood loss of 600 mL. With the same ventilator settings, her oxygenation remained stable (SpO2 95–98%) and plateau pressure decreased slightly after delivery (Fig. 1B).

The patient’s PaO2/FiO2 ratio improved over the following several days, and lung mechanics remained relatively stable (Fig. 1C and E). She required deep sedation and, at times, neuromuscular blockade to maintain ventilator synchrony. Prednisone was given for persistently poor expiratory flow despite inhaled bronchodilators. Ertapenem was given for an extended-spectrum-beta-lactamase–producing...
Escherichia coli urinary tract infection. She was extubated on postoperative day 10 (illness day 17) and discharged home in good condition on postoperative day 15.

The newborn was resuscitated by the neonatal team and intubated for respiratory distress. Chest radiography showed diffuse bilateral granular and hazy opacities concerning for mild edema or evolving respiratory distress syndrome (Appendix 2, available online at http://links.lww.com/AOG/B896); a dose of surfactant was given. Laboratory test results showed leukopenia, neutropenia, lymphopenia, mild acidosis, and normal lactate (Appendix 3, available online at http://links.lww.com/AOG/B896). Within hours of birth, the neonate was extubated and placed on continuous positive airway pressure ventilation. Oral and nasopharyngeal swabs (at 24 hours, 48 hours, and 14 days) and rectal swab (at 48 hours) were negative for SARS-CoV-2. Coronavirus disease 2019 immunoglobulin (Ig) G and IgM serologies drawn on day of life 5 were negative. Placental pathology showed acute chorioamnionitis, with no funisitis or histologic evidence of other placental infections, such as syphilis, toxoplasmosis, rubella, cytomegalovirus, or herpes simplex virus. At 16 days of life, the neonate was clinically stable on high-flow nasal cannula at 3 L/min and 21% FiO₂, at full nasogastric tube feeds, and had normal findings on neurologic examination.

**DISCUSSION**

Here we describe our multidisciplinary approach to the care of this patient. Standard management of ARDS, including lung-protective ventilation (low tidal volume, limited plateau pressure, higher PEEP, permissive hypercapnia)⁷ and supportive therapies (conservative fluid management, prone positioning, neuromuscular blockade, inhaled vasodilators, and extracorporeal life support)⁸,⁹ has not been rigorously studied in COVID-19 infection. Our case is consistent with some reports of ARDS from COVID-19 infection, suggesting that severe hypoxemia can occur in

<table>
<thead>
<tr>
<th>Measure</th>
<th>Reference Range</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3, POD1</th>
<th>Day 4, POD2</th>
<th>Day 5, POD3</th>
<th>Day 6, POD4</th>
<th>Day 7, POD5</th>
<th>Day 8, POD6</th>
<th>Day 9, POD7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>12.0–15.5</td>
<td>13.0</td>
<td>12.0</td>
<td>10.0</td>
<td>9.3</td>
<td>8.4</td>
<td>9.0</td>
<td>10.0</td>
<td>9.8</td>
<td>9.6</td>
</tr>
<tr>
<td>White blood cell count (×10⁹/L)</td>
<td>3.4–10.0</td>
<td>8.3</td>
<td>14.7</td>
<td>19.5</td>
<td>17.0</td>
<td>9.8</td>
<td>13.2</td>
<td>14.7</td>
<td>15.0</td>
<td>14.2</td>
</tr>
<tr>
<td>Lymphocyte count (×10⁹/L)</td>
<td>1.0–3.4</td>
<td>0.8</td>
<td>0.44</td>
<td>1.81</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Platelet count (×10⁹/L)</td>
<td>140–450</td>
<td>124</td>
<td>141</td>
<td>179</td>
<td>212</td>
<td>199</td>
<td>269</td>
<td>303</td>
<td>305</td>
<td>347</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>Less than 7.5</td>
<td>108</td>
<td>NA</td>
<td>151.8</td>
<td>NA</td>
<td>140.9</td>
<td>NA</td>
<td>173.6</td>
<td>NA</td>
<td>300.5</td>
</tr>
<tr>
<td>Procalcitonin (micrograms/L)</td>
<td>Less than 0.26</td>
<td>0.3</td>
<td>0.24</td>
<td>0.17</td>
<td>NA</td>
<td>0.09</td>
<td>NA</td>
<td>0.05</td>
<td>NA</td>
<td>0.07</td>
</tr>
<tr>
<td>Troponin (micrograms/L)</td>
<td>Less than 0.05</td>
<td>NA</td>
<td>NA</td>
<td>Less than 0.02</td>
<td>NA</td>
<td>Less than 0.02</td>
<td>NA</td>
<td>Less than 0.02</td>
<td>NA</td>
<td>Less than 0.02</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.55–1.02</td>
<td>0.66</td>
<td>0.55</td>
<td>0.64</td>
<td>0.67</td>
<td>0.54</td>
<td>0.53</td>
<td>0.57</td>
<td>0.52</td>
<td>0.50</td>
</tr>
<tr>
<td>Aspartate transaminase (units/L)</td>
<td>5–44</td>
<td>32</td>
<td>32</td>
<td>23</td>
<td>19</td>
<td>39</td>
<td>27</td>
<td>22</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Alanine transaminase (units/L)</td>
<td>10–61</td>
<td>38</td>
<td>35</td>
<td>25</td>
<td>21</td>
<td>22</td>
<td>24</td>
<td>24</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>Alkaline phosphatase (units/L)</td>
<td>38–108</td>
<td>71</td>
<td>71</td>
<td>61</td>
<td>72</td>
<td>75</td>
<td>69</td>
<td>77</td>
<td>76</td>
<td>74</td>
</tr>
<tr>
<td>Prothrombin time (sec)</td>
<td>11.7–15.1</td>
<td>NA</td>
<td>12.6</td>
<td>12.3</td>
<td>12.5</td>
<td>12.6</td>
<td>13.4</td>
<td>13.7</td>
<td>14.9</td>
<td>15.6</td>
</tr>
<tr>
<td>Ferritin (micrograms/L)</td>
<td>12–160</td>
<td>NA</td>
<td>NA</td>
<td>187</td>
<td>NA</td>
<td>216</td>
<td>NA</td>
<td>178</td>
<td>NA</td>
<td>224</td>
</tr>
<tr>
<td>Lactate dehydrogenase (units/L)</td>
<td>102–199</td>
<td>NA</td>
<td>NA</td>
<td>226</td>
<td>NA</td>
<td>280</td>
<td>NA</td>
<td>307</td>
<td>NA</td>
<td>319</td>
</tr>
<tr>
<td>Fibrin D-dimers (ng/mL)</td>
<td>Less than 500</td>
<td>870</td>
<td>NA</td>
<td>1,908</td>
<td>808</td>
<td>NA</td>
<td>881</td>
<td>NA</td>
<td>1,788</td>
<td></td>
</tr>
<tr>
<td>Respiratory viral panel*</td>
<td>Negative</td>
<td>Negative</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

POD, postoperative day; NA, not applicable.
* Included testing for influenza A and B, adenovirus, metapneumovirus, rhinovirus, and parainfluenza 1–4.

© 2020 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
the setting of relatively preserved lung compliance (i.e., lung stiffness) and dead space (i.e., amount of lung not participating in gas exchange)—which may reflect heterogeneity in the disease or a divergence from classic ARDS (Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a "typical" acute respiratory distress syndrome [letter]. Am J Respir Crit Care Med 2020 Mar 30 [Epub ahead of print]). The patient met criteria for moderate ARDS, but initial lung compliance after intubation was nearly normal. With usual ventilator management for ARDS, including upward PEEP titration, we saw the unexpected effect of lung overdistension, evidenced by decreased lung compliance and worsened hypercarbia indicating increased dead space.

Management of ARDS from COVID-19 infection is further complicated by pregnancy considerations. Normal physiologic changes in pregnancy, namely increased minute ventilation, reduced functional residual capacity, upward displacement of the diaphragm, increased chest wall compliance, and increased oxygen consumption, complicate management of these patients (see Table 1 in American College of Obstetricians and Gynecologists Practice Bulletin No. 211). Additionally, maternal hypoxemia and changes to uteroplacental blood flow may cause fetal hypoxia. Although prone positioning and extracorporeal life support have been described in pregnant patients, there are technical and anatomic challenges. These factors are compounded by infectious risks to health care professionals caring for critically ill patients with COVID-19 infection.

Early delivery in ARDS has been described as a therapeutic option for deteriorating patients, with possible benefit from changes in cardiopulmonary physiology. In one series of 10 patients intubated for respiratory failure, delivery resulted in reduced FiO2 within 24 hours but unchanged PEEP and plateau pressure. Rationale for early delivery in our case included: 1) the patient’s rapid deterioration over less than 24 hours, 2) the lack of improvement in oxygenation on 80–100% FiO2 despite optimization of ventilator settings and supportive therapies, 3) the opportunity to safely transport the patient to the operating room, and 4) the understanding that delivery may decrease maternal oxygen consumption and improve lung mechanics.

Our patient remained stable intraoperatively and, within 12 hours postpartum, had an improved PaO2/FiO2 ratio (as high as 260) and static compliance (from 33 to 50 mL/cmH2O) (Fig. 1C). Lung volumes also significantly improved (Fig. 2). Little information exists on ARDS in pregnancy, particularly from COVID-19 infection, and the risks and benefits of early delivery should be individualized in each case, prioritizing maternal stability over acute fetal status.

**Fig. 1.** Ventilator flowsheet during maternal hospitalization. **A.** Time of intubation: 02:00. **B.** Time of transport to operating room, FiO2 at 100% and inhaled nitric oxide at 20 ppm: 18:45; end of cesarean delivery: 19:45; inhaled nitric oxide off. **C.** Inhaled nitric oxide off. **D.** Paralysis initiated. **E.** Paralysis weaned and spontaneous mode ventilator initiated. *Periods of desaturation with ventilator dysynchrony.*

Concerns have been raised about worse COVID-19 outcomes with prolonged steroid therapy in the nonpregnant population. However, the course of antenatal corticosteroids for fetal lung maturity is of short duration and is recommended in patients at less than 34 weeks of gestation at risk for preterm birth. Antenatal corticosteroids can be given in patients with diabetes after full consideration of the potential risks and benefits. In our patient, we felt that the benefits outweighed the risks given her very preterm gestation; she did develop hyperglycemia after antenatal corticosteroid administration (as high as 279 mg/dL), subsequently controlled with increasing insulin doses. Similarly, magnesium sulfate for fetal neuroprotection should be considered even in women with respiratory symptoms, though evidence is limited on how to monitor these patients for toxicity. Oxygen saturation and respiratory rate should be followed closely and dosage and volume adjustments made for patients with renal dysfunction or pulmonary edema. Care must be individualized, balancing known fetal benefits of antenatal corticosteroids and magnesium against hypothetical risks to the mother.

The most effective treatment for COVID-19 infection is unknown. At our institution, hospitalized adults with COVID-19 infection are enrolled in the Adaptive COVID-19 Treatment Trial (ClinicalTrials.gov, NCT04280705); however, pregnant patients are excluded. Therefore, we obtained and administered compassionate use remdesivir for this patient after reviewing internal data shared by Gilead Sciences on the safety of remdesivir in pregnancy. Hydroxychloroquine is considered safe in pregnancy and has been used to treat COVID-19 infection, although its efficacy is unknown and there is increasing data on cardiotoxicity. In this patient, hydroxychloroquine was initiated before transfer but later discontinued owing to QTc prolongation, a known side effect. Convalescent plasma was considered but not available.

Fig. 2. Maternal chest radiography. A. Imaging on admission showed multifocal consolidations and reduced lung volumes. B. Repeat imaging on postoperative day 3 showed improved lung volumes and decreasing bilateral opacities.

Considerable uncertainty remains regarding vertical transmission of SARS-CoV-2, which has been detected in maternal sputum, pharyngeal, nasopharyngeal, and stool specimens but not in maternal blood, amniotic fluid, vaginal mucus, placenta, or breast milk. Reports exist of neonates positive for SARS-CoV-2 by oral and nasopharyngeal swabs within 36–48 hours after caesarean delivery and of neonates producing SARS-CoV-2–specific IgM.

Preterm neonates may be at particular risk for perinatal COVID-19 infection. The fetus is primed toward immunologic tolerance in a semi-allogeneic uterine environment and may not mount effective inflammatory responses to infection. Additionally, passive transfer of protective maternal immunoglobulins does not reach maximum until term, with 28–30-week neonates having about 50% of maternal IgG levels. The immature skin integrity of preterm neonates may also be a risk factor for perinatal transmission.

The neonate in our case had swabs for SARS-CoV-2 and COVID-19 IgG and IgM that were negative. Although placental pathology showed acute chorioamnionitis, we could find no clinical evidence of this in the mother or the neonate. Given the paucity of data on COVID-19 infection in preterm neonates at less than 30 of gestation, this neonate was kept under novel respiratory isolation measures until 14 days of life. Further research is needed on risk factors and prevention of perinatal COVID-19 infection, including infection-control measures during delivery and in exposed premature neonates requiring ongoing hospitalization.

There are few reports of pregnant women with severe COVID-19 infection, particularly in the very preterm period. Our patient’s condition decompensated quickly, and, after multidisciplinary consideration, we proceeded with urgent delivery with acceptable maternal and fetal outcomes. We highlight our perspectives on this complex patient, for whom decision making required balancing maternal and fetal well-being, as well as minimizing undue risk to
health care professionals. We also advocate for early discussions with patients regarding designating a medical proxy and goals of care for herself and the fetus, particularly in a time of widespread hospital visitor restrictions and potential for rapid clinical deterioration from COVID-19 infection.

REFERENCES


PEER REVIEW HISTORY